This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Barnes Jewish Hospital Neurosurgeons Treat 1000th Patient Using VISIUS IMRI

Ceiling-mounted high-field intraoperative MRI provides improved results and patient outcomes

MINNEAPOLIS, May 20, 2014 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced that Barnes-Jewish Hospital in St. Louis is the first U.S. hospital to use VISIUS ® iMRI for more than 1,000 procedures. This clinical experience and published evidence by the neurosurgical team has shown that intraoperative MRI is an effective tool for improving results and outcomes for patients undergoing brain surgery.

"Using MR during procedures instead of after, we can truly measure what we have accomplished and go back and resect more tumor before actually completing the surgery. We cannot see this tumor without iMRI. Our published experience has shown this leads to better long-term survival and quality of life," said Dr. Michael Chicoine, Barnes-Jewish neurosurgeon and associate professor of neurological surgery at Washington University School of Medicine. "While the iMR is among the tools we use, the patients are the real beneficiaries as we limit the risks for returning to surgery."

Installed in 2008, the VISIUS Surgical Theatre at Barnes Jewish Hospital is a three-room suite where a high-field MR travels between two hybrid operating rooms using ceiling-mounted rails with a third room in the middle for storing the scanner when not in use. The high-quality MR imaging provides surgeons with on-demand access to real-time updated image detail during the procedures without moving the patient.

IMRIS CEO and President Jay D. Miller noted, "This milestone sets the neurosurgical team at Barnes-Jewish and Washington University apart in their pioneering leadership and experience. Their expertise and that of other VISIUS installations is moving iMR towards the standard of care for certain tumors and greater utilization for other neurosurgical procedures."

IMRIS supports ongoing studies and research regarding the use and benefits of ceiling-mounted iMRI through an expanding Washington University School of Medicine multicenter neurosurgical database called I-MiND (IMRIS Multicenter iMRI Neurosurgery Database) which includes a growing number of leading hospitals. IMRIS also produces proprietary head fixation devices, imaging coils, and OR tables for use in this unique and multifunctional intraoperative environment.

About IMRIS IMRIS (NASDAQ: IMRS; TSX: IM) is a global leader in providing image guided therapy solutions through its VISIUS Surgical Theatre - a revolutionary, multifunctional surgical environment that provides unmatched intraoperative vision to clinicians to assist in decision making and enhance precision in treatment. The multi-room suites incorporate diagnostic quality high-field MR, CT and angio modalities accessed effortlessly in the operating room setting. VISIUS Surgical Theatres serve the neurosurgical, spinal, cardiovascular and cerebrovascular markets and have been selected by 57 leading medical institutions around the world.

SOURCE IMRIS Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs